Navigation Links
Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
Date:11/19/2010

NEW YORK, Nov. 19, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival (PFS) when compared to sorafenib, in the study population.  Consistent with previous analyses, axitinib demonstrated a generally manageable safety profile in this study.

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

"It is gratifying that in this trial axitinib provided significant benefit to patients with advanced RCC whose disease had progressed after 1st-line therapy," said Dr. Mace Rothenberg, senior vice president of Clinical Development and Medical Affairs for Pfizer's Oncology Business Unit.  "These results provide insight into the potential value of axitinib as part of a sequential treatment approach in patients with advanced RCC.  We will work with health authorities to determine possible filing options for axitinib for use in patients with advanced RCC."

Each year, approximately 210,000 people worldwide are diagnosed with kidney cancer and nearly 102,000 people are expected to die from the disease.  Within the last five years, great advances have been made in the treatment of patients with advanced RCC, the most prevalent form of kidney cancer.  However, five-year survival rates for patients with advanced RCC remain low, at around 20 percent.

About the Investigational Agent Axitinib

Axitinib is an oral and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2 and 3.  VEGF receptors 1, 2 and 3 appear to have roles in tumor growth, vascular angiogenesis and metastatic progression of cancer (the spread of
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Pfizer Launches New Advil® Congestion Relief and Offers 100 Holiday Shoppers Literal Decongestion From Black Friday Crowds
2. Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
3. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
4. Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
5. Pfizer Declares an 18-Cent Fourth-Quarter 2010 Dividend
6. Pfizers Lyrica® (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan
7. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
8. Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil
9. Biocon and Pfizer Enter Into Global Commercialization Agreement
10. Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
11. Pfizer Completed Acquisition of FoldRx
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... 7, 2015   Bionik Laboratories Corp. ... with a core focus in robotic exoskeleton technology ... "Company"), announced today that it has completed an ... consisting of its common stock and warrants for ... a private placement transaction.  This equity financing is ...
(Date:7/7/2015)... Oasmia Pharmaceutical AB, a ... human and veterinary oncology, today announced that it ... the United States , designed to generate ... therapeutic.      (Logo: http://photos.prnewswire.com/prnh/20150420/740096) , ... Paccal Vet-CA1 was previously distributed by ...
(Date:7/7/2015)...  Monopar Therapeutics LLC, an emerging biopharmaceutical company focusing ... and CEO, Chandler D. Robinson MD, MBA, ... Award. The British Council selected one recipient from each ... , and the United States ... who have leveraged their U.K. education in their subsequent ...
Breaking Medicine Technology:Bionik Laboratories Completes US$13.1 Million Private Placement 2Bionik Laboratories Completes US$13.1 Million Private Placement 3Oasmia Pharmaceutical Launches US Brand and Sales Platform 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 2Monopar Therapeutics Announces Founder And CEO Chandler Robinson Awarded The British Council's Education U.K. Alumni Award 3
... pharmaceutical and medical device companies evolve, market research ... refining current ones to support intelligent planning and ... beginning to explore different types of technological advances ... external data collection and internal asset creation. ...
... 2012   CareFusion Corp. (NYSE: CFN ... that its board of directors authorized the repurchase of ... (Logo:  http://photos.prnewswire.com/prnh/20100706/CAREFUSIONLOGO ) "This ... potential and our commitment to increasing shareholder value," said ...
Cached Medicine Technology:Pharmaceutical Industry Leveraging New Tools to Overcome Challenges in Market Research 2CareFusion Announces $500 Million Share Repurchase Program 2CareFusion Announces $500 Million Share Repurchase Program 3
(Date:7/7/2015)... ... July 07, 2015 , ... ... to interact with fans and provide frozen yogurt offerings at Live Nation's amphitheaters ... truck will be on site at concerts throughout the summer and brand ambassadors ...
(Date:7/7/2015)... ... July 07, 2015 , ... Leading ... expert Jay Warden as Senior Vice President, heading the firm’s Healthcare Advisory Services ... the best solutions to healthcare providers’ needs in ways that strengthen their position ...
(Date:7/7/2015)... ... 07, 2015 , ... Ticket Down is a reputable source of authentic tickets for the 2015 ... vs. Honduras at the Toyota Stadium. , The 2015 CONCACAF Gold Cup is ... The tournament, being held on American soil, will kick off in Frisco, CA from the ...
(Date:7/7/2015)... ... 2015 , ... Greatist today announced the acquisition of Blood, ... the most fun activities to do with friends. , The acquisition of BSC strengthens ... opportunity for events, e-commerce, and brand partnerships. , “I’ve been a huge fan of ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... global provider of advanced delivery technologies and development solutions for drugs, biologics ... licensing agreement with Excelimmune, Inc. to access its antibody combination therapy (ACT) ...
Breaking Medicine News(10 mins):Health News:sweetFrog Mobile Trucks to Offer Froyo at Live Nation Venues 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 2Health News:Hammes Company Hires Jay Warden to Lead Healthcare Advisory Services 3Health News:Panama vs Haiti & USA vs Honduras CONCACAF Group A Tickets at Toyota Stadium: Ticket Down Slashes Ticket Prices for Haiti vs Panama & USA vs Honduras in Frisco/Dallas 2Health News:Panama vs Haiti & USA vs Honduras CONCACAF Group A Tickets at Toyota Stadium: Ticket Down Slashes Ticket Prices for Haiti vs Panama & USA vs Honduras in Frisco/Dallas 3Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2
... ... responsibility to remedy the tragic legacy of decades of asbestos use requires funding research ... ... Mesothelioma Applied Research Foundation today publicly praised the United Kingdom’s Ministry of Justice for ...
... ... companies highest priorities; therefore any allegations made about the safety of the company,s products are ... ... been committed to providing products that empower people to lead healthier lives. Product safety and ...
... ... ... ... ...
... , ... Jay Berkowitz, founder of TenGoldenRules.com, presents quality employee communications through use of the ... ... top keynote speaker and founder of TenGoldenRules.com, has been asked to present ...
... ... ... ... ...
... of Public Health, Walter Reed Army Institute of Research, and ... that the risk of multiple sclerosis (MS) increases by many ... implicates EBV as a contributory cause to multiple sclerosis. The ... Annals of Neurology and will appear in a later print ...
Cached Medicine News:Health News:U.K.: Justice for Asbestos Disease Victims Requires Mesothelioma Research Funding 2Health News:U.K.: Justice for Asbestos Disease Victims Requires Mesothelioma Research Funding 3Health News:NOW Foods Response to Fish Oil and PCB Concerns 2Health News:National Healthcare Leaders in San Francisco to Address Health Reform and Payment Reform 2Health News:National Healthcare Leaders in San Francisco to Address Health Reform and Payment Reform 3Health News:National Healthcare Leaders in San Francisco to Address Health Reform and Payment Reform 4Health News:Keynote Speaker Presents Top Business Plan For Internal Communication Through Social Media 2Health News:American Dental Association President Testifies Before IOM Committee on Access to Oral Health Care 2Health News:American Dental Association President Testifies Before IOM Committee on Access to Oral Health Care 3Health News:Researchers find further evidence linking Epstein-Barr virus and risk of multiple sclerosis 2
The 920M PLUS handheld pulseoximeter provides on-the-spot bloodoximetry and heart rate readings....
Rad-5 signal extraction pulse oximeter™...
... 3100 is a small, lightweight ... worn comfortably on the patients ... activities and for overnight studies, ... WristOx is intended to give ...
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
Medicine Products: